Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma
Sign Up to like & getrecommendations! Published in 2025 at "Current Oncology"
DOI: 10.3390/curroncol32030144
Abstract: Patients with advanced melanoma who progress on standard-dose ipilimumab (Ipi) + nivolumab continue to have poor prognosis. Studies support a dose–response activity of Ipi, and one promising combination is Ipi 10 mg/kg (Ipi10) + temozolomide… read more here.
Keywords: ipi10 tmz; standard; dramatic responses; dose ipilimumab ... See more keywords